4-Aethyl-tetrahydrothiopyranol-(4) | 38447-83-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 英文名称: 4-Aethyl-tetrahydrothiopyranol-(4)
• 英文别名: 4-ethyl-tetrahydro-thiopyran-4-ol；4-Aethyl-tetrahydro-thiopyran-4-ol；4-Ethylthian-4-ol；4-ethylthian-4-ol
• CAS: 38447-83-5
• 化学式: C₇H₁₄OS
• 分子量: 146.254
• InChiKey: MQUGLRINFQDYCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Aethyl-tetrahydrothiopyranol-(4) 在 草酸 作用下， 生成 γ-Ethylpentamethylensulfid
  参考文献：
  名称：

  Onesta; Castelfranchi, Gazzetta Chimica Italiana, 1959, vol. 89, p. 1127,1136

  摘要：

  DOI：
• 作为产物：
  描述：

  3,3'-硫代二丙酸二甲酯 在 乙醚 、 硫酸 、 sodium methylate 、 溶剂黄146 、 甲苯 作用下， 生成 4-Aethyl-tetrahydrothiopyranol-(4)
  参考文献：
  名称：

  Onesta; Castelfranchi, Gazzetta Chimica Italiana, 1959, vol. 89, p. 1127,1136

  摘要：

  DOI：

文献信息

• Nicotinamide Derivatives
  申请人：Crawforth James Michael

  公开号：US20110306597A1

  公开（公告）日：2011-12-15

  The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the treatment of allergic and respiratory conditions.

  本发明涉及公式(I)的化合物及其药学上可接受的盐和溶剂，其中取代基在此定义，以及包含这种化合物的组合物，以及这种化合物用于治疗过敏和呼吸系统疾病的用途。
• PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20140206711A1

  公开（公告）日：2014-07-24

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α 2B , α 1B or α 2A . The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

  这份披露涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。提供了包括这些化合物的药物组合物，以及使用这些化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。这些化合物可以结合并拮抗受体α2B、α1B或α2A。这些化合物可以用于治疗，例如，（i）降低血压和/或（ii）促进肾血流和/或（iii）降低或抑制钠重吸收，或者调节血糖水平，增加胰岛素分泌，并治疗对增加胰岛素产生反应的疾病或状况。这些化合物还可以用于治疗预计会对降低血压产生反应的疾病或状况。特别描述了使用这些化合物治疗心血管、肾脏障碍或2型糖尿病的用途。
• PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Medivation Technologies, Inc.

  公开号：US20150258075A1

  公开（公告）日：2015-09-17

  This disclosure is directed to pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. The compounds may bind to and antagonize receptor α2B, α1B or α2A. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption, or to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. The compounds may also be used to treat diseases or conditions that are expected to be responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular, renal disorders or type 2 diabetes is particularly described.

  本公开涉及吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚衍生物。所述化合物的制药组合物也提供，以及使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。该化合物可能结合并拮抗α2B、α1B或α2A受体。该化合物可能用于治疗，例如：（i）降低血压和/或（ii）促进肾血流和/或（iii）减少或抑制钠重吸收，或调节血糖水平，增加胰岛素分泌并治疗预计对胰岛素产生增加反应的疾病或情况。该化合物还可用于治疗预计对血压降低有反应的疾病或情况。特别描述了使用该化合物治疗心血管、肾脏疾病或2型糖尿病的用途。
• URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP2740728A1

  公开（公告）日：2014-06-11

  The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, R1 represents a hydrogen atom, a C1-10 alkyl group, a C2-6 alkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; R2 represents a hydrogen atom, a halogen atom, a cyano group, -NRcRd, -N=CHN(CH3)2, or an C1-3 alkyl group: Ar1 and Ar2 independently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient.

  本发明提供了一种由通式(I)代表的尿嘧啶衍生物或其生理学上可接受的盐(在式中，R1代表氢原子、C1-10烷基、C2-6烯基或3～6元饱和或4～6元不饱和脂肪环基，其可含有1～2个独立地选自N、O和S组成的组的杂原子；R2代表氢原子、卤素原子、氰基、-NRcRd、-N＝CHN(CH3)2或C1-3烷基：Ar1 和 Ar2 独立地代表 5 至 6 元芳香环基，其中可含有 1 至 3 个独立地选自 N、O 和 S 组成的杂原子；L 代表 6 元芳香环基，其中可含有 1 至 4 个氮原子、吡唑基、三唑基或咪唑基）；与弹性蛋白酶相关的各种炎症疾病的治疗剂或预防剂包括该化合物或类似物作为活性成分。
• Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ROR[γ]
  申请人：Phenex Pharmaceuticals AG

  公开号：US10301272B2

  公开（公告）日：2019-05-28

  The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1′), (100), (100′), (200) and (200′) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

  本发明提供了孤儿核受体RORy的调节剂，以及通过向人类或有需要的哺乳动物施用这些新型RORy调节剂来治疗RORy介导的疾病的方法。具体地说，本发明提供了式(1)、(1′)、(100)、(100′)、(200)和(200′)的含羧酰胺或磺酰胺的环状化合物及其对映体、非对映体、同系物、/V-氧化物、溶剂和药学上可接受的盐。